RxDoctor Payments Data

Katerina Devore

Family · Dardanelle, ARNPI 1275040511

Payments from drug & device makers

$700in general payments, 2019–2025

Across 41 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$302
  • Novo Nordisk$69
  • Pfizer$53
  • GSK$47
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$43
  • Amgen$38
  • plus $147 from 9 others

What the payments were for

  • Food & beverage$700100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$700 in reported general payments places this provider in the 60th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$21,853
Medicare patients
144
Services billed
307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide177$210,396
OzempicSemaglutide85$79,875
LinzessLinaclotide60$55,245
JardianceEmpagliflozin44$51,874
EliquisApixaban71$50,598
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$38,200
JanuviaSitagliptin Phosphate17$20,157
TrulicityDulaglutide18$18,529
Tresiba Flextouch U-200Insulin Degludec27$17,253
Tresiba Flextouch U-100Insulin Degludec24$15,920
SymbicortBudesonide/Formoterol Fumarate56$13,342
Lantus SolostarInsulin Glargine,hum.Rec.Anlog60$9,863
Humalog Kwikpen U-100Insulin Lispro20$7,089
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$6,026
Gabapentin332$5,232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$69$79,87585 claims
AbbVieLinzess$302$55,24560 claims
PfizerEliquis$53$50,59871 claims
GSKTrelegy Ellipta$47$38,20047 claims
AstraZenecaSymbicort$14$13,34256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,103 family providers in Arkansas.

Other family in Dardanelle

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →